Active clinical trials for "COVID-19"

Aim: To investigate the efficacy of systemic corticosteroids in treatment for Post-COVID-19 Interstitial Lung Disease. Method: Method: In this multi-centre, prospective, randomised controlled open label clinical trial, patients are divided into two arms: standard treatment arm and standard plus systemic corticosteroid arm. After twelve weeks; clinical, functional, and radiological improvement will being assessed as primary outcomes.

The purpose of this study is to objectively identify and address social determinants of health (SDOH) priorities and barriers in Latino patients who survived or are vulnerable to COVID-19, and to understand the consequences of COVID-19 survivorship in local Latino communities.

Explore the effects on immune response to include a potential third vaccine for the cancer cohort.

An interventional, randomized, double-blind, placebo-controlled study will be conducted to investigate the effect of a probiotic strain on the immune response in participants positive for SARS-CoV-2 infection. The study duration will be 28 days, which includes 4 weeks product administration. Participants will be randomized assigned to one of the two study groups: the control group with placebo consumption and a probiotic consumption group.

To determine whether an individually prescribed homeopathic medicine has an effect greater than a placebo and is a viable treatment option to improve fatigue and quality of life for patients suffering from the symptoms of Post-acute COVID-19 Syndrome. The researchers hope to achieve this goal by conducting a clinical trial that is scientifically rigorous and clinically relevant. Expected results of this pilot study will be to obtain sufficient experience and preliminary feasibility data to justify a larger clinical trial of this hypothesis.

In this trial, patients that are severely affected by the disease COVID-19 will either receive infliximab, an anti-inflammatory drug, or standard therapy. Infliximab is a drug that inhibits inflammation by blocking a molecule called TNFα. The patients receive the drug via an infusion into a vein. The primary goal of this trial is to see whether the drug infliximab affects how many people died from COVID-19 after 28 days by comparing patients receiving the drug in addition to standard therapy with patients only receiving standard therapy. Furthermore, this trial will look at whether the drug is safe to use in these patients, whether it has an effect on the inflammation and whether it can affect how ill patients are after surviving the disease. The trial is conducted in more than one hospital. As COVID-19 is responsible for a global pandemic, positive results of this trial could affect patients, healthcare and economic systems worldwide.

To study the efficacy and safety of icatibant in adult patients admitted to hospitalization units for pneumonia caused by COVID-19, without mechanical ventilation, 10±1 days after starting treatment or discharge from hospital if this occurs before 10 days.

This study is a randomized, double-blinded, and placebo controlled phase III clinical trial which aims to investigate the superiority of hydroxychloroquine, favipiravir or hydroxychloroquine + favipiravir treatment, initiated especially in the early period in the treatment of COVID-19, over the patients being followed up with placebo in adults aged 18~59 Years.

In December 2019, a cluster of pneumonia cases, caused by a newly identified βcoronavirus, occurred in Wuhan, China.1 The World Health Organization (WHO) officially named the disease as coronavirus disease 2019 (COVID-19), and the International Committee on Taxonomy of Viruses named the virus as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).2 On 11 March 2020, the WHO declared the epidemic of COVID-19 as a pandemic.3 The pandemic crisis prioritises critical care for those coronavirus (COVID-19) patients who have been most profoundly affected, and hospitals, staffing, and working practices have been radically adjusted to accommodate this.4,5 The healthcare industry, in particular, has been overwhelmed by the effect of COVID-19 on healthcare resources. This has been underscored by providers concerned about emotional strain and physical exhaustion, access to personal protective equipment (PPE) and medical equipment, workplace exposure to COVID-19 and disease transmission to family members.6 Physicians are essential for any health-care system and at the frontline defense against the COVID-19 pandemic. They play a crucial role in diagnosis, treatment, prevention of disease spread, and public education during this pandemic. Moreover, they are frequently exposed to infected individuals with COVID-19, making them at higher risk of infection than others.7 Anesthesia is one such specialty whose residents are uniquely at risk of exposure to infection in the operating room or ICU. Residents reported that their learning schedule is distorted in our hospital regarding skills because of increase ICU rotations, cancelled elective surgeries, missing one or two of the major rotations. Also, lecturers were stopped and replaced by E-learning after a long period. Examination schedule was changed and so the research schedule. Infection of the trainees (or a member of a family) had a great emotional and physical impact on them. COVID-19 will not go away any time soon, and therefore the new balance between service provision and training needs to be agreed in a sensitive way to avoid further frustration amongst trainees. Adaptations to these circumstances have delivered new forms of teaching and supervision. We design this cross-sectional study and implement a survey that included a 58-question to accomplish the specific aims of the present study through comparisons of two groups of residents and to provide plans for the training programme to be less affected by pandemics.

The objective of the study is to evaluate the efficacy and safety of two different doses of raloxifene orally administered compared to placebo in patients with early diagnosis of paucisymptomatic COVID-19. Primary objectives: Evaluation of the effectiveness of therapy in reducing the proportion of subjects who still have viruses in the upper airways after 7 days of therapy Evaluation of the effectiveness of therapy in reducing the proportion of subjects who requires supplemental oxygen therapy and/or mechanical ventilation within 14 days of starting therapy Secondary objectives: Evaluation of the effectiveness of therapy in reducing the proportion of subjects who still have viruses in the upper airways after 14 and 28 days of therapy Evaluation of the effectiveness of therapy in reducing the proportion of subject patients who requires supplemental oxygen therapy and/or mechanical ventilation within 7 or 28 days of starting therapy 7, 14 and 28 days drug safety and tolerability profile Assessment of body temperature, blood and biochemical parameters between T0 and T28